Mallinckrodt, Takeda Sue Zydus to Block Copies of Amitiza Drug

Mallinckrodt’s Sucampo unit and Takeda said Zydus Cadila’s proposed generic version of Amitiza, used to treat opioid-induced constipation, infringes five patents owned by Sucampo and licensed to Takeda.

• Mallinckrodt and Takeda are seeking a court order blocking copies until the patents have expired, and providing for cash compensation if copies are made before then, according to complaint filed Friday in federal court in Trenton, New Jersey
• Patents expire in September 2025, January 2027 and October 2027: FDA Orange Book
• Amitiza had sales and royalties of $157.6 million during the first nine months of 2019, up from $119.2 million ...